|Harvard Medical School, PhD||2004|
|Genetics, Molecular and Cell Biology|
|Rutgers College, BA||1999|
Kevin is the interim president of Editas Medicine and a principal at Polaris Partners. He joined Polaris in 2004 and focuses on investments in health care.
Kevin is a co-founder of Genocea Biosciences and Sirtris Pharmaceuticals (acquired by GSK) and was the founding CEO at Visterra Inc. (formerly Parasol Therapeutics).
He currently represents Polaris as a director of InSeal Medical, Genocea Biosciences, Kala Pharmaceuticals, Neuronetics, Inc., Visterra Inc., Taris Biomedical and Vets First Choice.
Additionally, he is a board observer to Arsenal Medical and 480 Biomedical.
Kevin holds a Ph.D. in genetics from Harvard Medical School. His doctoral research focused on the molecular regulation of caloric restriction and on modulation of a novel class of protein deacetylases.